Seattle Genetics' breast cancer drug hits mark in pivotal trial

A pivotal trial of Seattle Genetics’ tucatinib in patients with HER2-positive breast cancer has met its primary endpoint. The data tee Seattle Genetics up to file for FDA approval of a TKI inhibitor it paid $614 million to acquire last year.